Skip to main content

Table 3 Time to progression of Endostar combined with chemotherapy versus chemotherapy alone for treating NSCLC

From: Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer

 

Endostar combined with PBDC (TTP, months)

PBDC alone (TTP, months)

T-value

95% CI

P-value

Wang JW 2005[11]

6.3

3.6

T = 12.02

1.815 to 2.91

0.000

Yang L 2005[12]

5.03

3.33

   

Liu J 2009[17]

6.2

3.4

   

Shi GY 2009[19]

6.1

3.7

df = 4

  

Zhang H 2011[24]

7.3

5.1

   

Mean ± SD

6.19 ± 0.80

3.83 ± 0.73

   
  1. 95% CI, 95% confidence interval; df, degree of freedom; SD, standard deviation; TTP, time to progression.